GSK advanced its seasonal influenza mRNA vaccine program (GSK4382276A) into late-stage clinical development following highly successful Phase 2 trial (NCT06431607) results. The reformulated candidate successfully elicited strong, durable immune responses against both influenza A and B strains in both younger and older adults.
- Key Details & Trial Results.
- Target: The study evaluated multiple modified, multivalent mRNA formulations.
- Participant Diversity: The trial enrolled 500 healthy participants split across two demographics: adults aged 18–64 and older adults aged 65–85.
- Efficacy: The vaccine candidate met all pre-defined success criteria, successfully hitting traditionally challenging influenza B strains alongside A strains.
- Safety: Interim data revealed a favorable safety and reactogenicity profile across all tested doses.
Strategic Advancements.
- Overcoming The “B Strain” Hurdle: Earlier versions of the mRNA vaccine proved potent against A strains but fell short against B strains. GSK’s reformulation successfully closed this gap, matching or outperforming conventional licensed vaccines.
- Full Control of the Platform: GSK acquired full development and manufacturing rights for its mRNA programs (including flu and COVID-19 candidates) from its former partner, CureVac, ensuring strategic autonomy moving forward.
- Future Market Entry: By pairing a scalable, rapidly adaptable mRNA platform with high immunogenicity in older adults—a demographic that traditionally requires enhanced protection—GSK is positioning itself to capture a significant share of the next-generation seasonal flu market.
For more information, you can review GSK’s official Phase 2 Press Release.
